A
Allogene Therapeutics, Inc. (ALLO)
NMS – Real Time Price. Currency in USD
2.26
-0.15 (-6.22%)
At close: Mar 27, 2026, 4:00 PM EDT
2.27
+0.01 (0.44%)
After-hours: Mar 27, 2026, 7:51 PM EDT
Get all premium features to the best stock analysis tool
NMS – Real Time Price. Currency in USD
2.26
-0.15 (-6.22%)
At close: Mar 27, 2026, 4:00 PM EDT
2.27
+0.01 (0.44%)
After-hours: Mar 27, 2026, 7:51 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 7.93 | 6.05 | 10 | |
| Quick ratio | 7.93 | 5.63 | 10 | |
| Debt to Equity | 0.28 | 0.30 | 8.0 | |
| Debt to Assets | 0.20 | 1.04 | 8.0 | |
| Interest coverage | -135.48 | -16.91 | 1.0 | |
| Weighted average score | 7.4 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 156K | 95K | 22K | N/A | N/A |
| Gross Profit | -14M | -14M | -14M | -12M | -12M |
| Operating Income | -336M | -314M | -257M | -207M | -207M |
| Net Income | -340M | -327M | -258M | -191M | -191M |
| EBITDA | -321M | -300M | -244M | -195M | -195M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 32.74 | 5.5 |
| Next quarter | N/A | 16.08 | 5.0 |
| Current year | N/A | 7.78 | 3.5 |
| Next year | 128118.94 | 1.5 | 6.5 |
| Weighted average score | 5.1 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | 6.26 | 10.53 | 7.79 | 7.0 |
| Y/Y | 999 | 35.25 | 39.29 | 25.32 | 10 |
| 3y average | -71.96 | 17.02 | 26.95 | 11.85 | 6.8 |
| 5y average | 136.65 | -1.73 | 13.45 | 2.44 | 5.5 |
| Weighted average score | 7.3 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Total debt $83.3M significantly exceeds cash reserves ($51.7M), raising financial stability concerns
Total current assets $257.7M exceed Total current liabilities $32.5M, highlighting excellent liquidity
Debt-to-equity ratio (0.3) is well below the industry average (0.3), showcasing prudent financial management
Interest coverage ratio (-135.5x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$27.6M limits the company's ability to reinvest or pay down debt